Reneo Pharmaceuticals (RPHM) KOL Event on STRIDE: Evaluating Mavodelpar in Patients with Primary Mitochondrial Myopathies (PMM)
About The Event
Join us in-person for a KOL event with Reneo Pharmaceuticals, featuring Amel Karaa, MD (Massachusetts General Hospital), PI of the STRIDE Study, who will discuss the unmet medical need and current treatment landscape for patients with primary mitochondrial myopathies (PMM).
The Reneo team will provide insight into the STRIDE study, a global, randomized, double-blind, 6-months, placebo-controlled clinical trial designed to assess the efficacy and safety of mavodelpar administered orally once daily to adult patients with PMM with mitochondrial DNA (mtDNA) defects. Topline data is expected in the fourth quarter of 2023.
A live question and answer session will follow the formal presentations.
Following the in-person event, there will be opportunity to meet with Dr. Karaa between 1:30 – 4:00 PM.